ASCO 2019: Atara Biotherapeutics updates on biomarker research

3 June 2019
atarabiotherapeutics-big

Immunotherapy specialist Atara Biotherapeutics (Nasdaq: ATRA) has presented clinical results relating to its biomarker research at the annual meeting of the American Society of Clinical Oncology (ASCO).

The Californian company is developing novel treatments for patients with cancer, autoimmune and viral diseases.

The firm recently  appointed Pascal Touchon as chief executive, poaching the former global oncology head from Novartis (NOVN: VX).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology